Pfizer's Centers for Therapeutic Innovation (CTI) is a unique joint drug discovery model focused on collaborating with leading academic medical centers to translate and transform concepts into breakthroughs that change patients' lives.
The CTI 2020 Call for Proposals (CFP) is focused on identifying novel therapeutic opportunities in the areas outlined below with application in Pfizer’s core research focus areas: oncology, inflammation & immunology, internal medicine and rare diseases.
CTI Collaborations include:
Submission Process
In consideration of COVID-19 impacts to all our work environments, Pfizer CTI will be holding one Call for Proposals this year which will be open for four months. The timelines are:
Submission entails a non-confidential 2-3 page overview of the target, mechanism, evidence for disease linkage, and the proposed therapeutic drug. At a high level, the pre-proposal should suggest how the therapeutic hypothesis could be tested in the clinic. Pre-proposals submitted to Pfizer CTI will be reviewed on a rolling basis.
Further information
For additional details about this opportunity including the Areas of Interest and Targets/Pathways of Focus, please click here. For further information about submitting a pre-proposal, please contact Andrew Bray (andrew.bray@monash.edu) or Chacko Joseph (chacko.joseph@monash.edu).
The CTI 2020 Call for Proposals (CFP) is focused on identifying novel therapeutic opportunities in the areas outlined below with application in Pfizer’s core research focus areas: oncology, inflammation & immunology, internal medicine and rare diseases.
CTI Collaborations include:
- Funding for project-specific research
- Hands-on collaboration from dedicated Pfizer drug-development experts
- Access to scientific/technological expertise and infrastructure at Pfizer
- Potential for in-licensing by Pfizer, which would include milestone and royalty payments
- Publishing rights
Submission Process
In consideration of COVID-19 impacts to all our work environments, Pfizer CTI will be holding one Call for Proposals this year which will be open for four months. The timelines are:
- Week commencing 1 June 2020: CTI Portal opens for non-confidential pre-proposal submission.
- 21 September 2020: Deadline for PIs to submit pre-proposals.
Submission entails a non-confidential 2-3 page overview of the target, mechanism, evidence for disease linkage, and the proposed therapeutic drug. At a high level, the pre-proposal should suggest how the therapeutic hypothesis could be tested in the clinic. Pre-proposals submitted to Pfizer CTI will be reviewed on a rolling basis.
Further information
For additional details about this opportunity including the Areas of Interest and Targets/Pathways of Focus, please click here. For further information about submitting a pre-proposal, please contact Andrew Bray (andrew.bray@monash.edu) or Chacko Joseph (chacko.joseph@monash.edu).
No comments:
Post a Comment